Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Oscillating Pulsed Electric Fields Strike Major Blow to Resistant Bacteria and Cancer

By BiotechDaily International staff writers
Posted on 29 Oct 2013
Image: Time lapse photos of three leukemia cells being treated with OPEF. Two of the three cells are literally shattered by the treatment (Photo courtesy of PRNewsFoto/Novobiotronics Inc.).
Image: Time lapse photos of three leukemia cells being treated with OPEF. Two of the three cells are literally shattered by the treatment (Photo courtesy of PRNewsFoto/Novobiotronics Inc.).
Oscillating pulsed electric field (OPEF) technology is delivering a one-two punch against cancer and antibiotic-resistant bacteria using a pulsed electronic signal that destroys cancer cells and disables antibiotic resistance in deadly methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas bacteria.

Novobiotronics (Saratoga Springs, NY, USA), a world leader in research on the biologic effects of OPEFs as a future nontoxic medical treatment, was the first company to confirm the capability of OPEFs to destroy 30%–60% of leukemia cells. In laboratory research, OPEF also demonstrated an ability to slow cancer growth by up to 60%. OPEF has also shown an ability to disarm antibiotic resistance in the lethal bacteria MRSA, rendering it susceptible to typically available antibiotics as well as inhibiting its growth.

Novobiotronics Inc., a nonprofit educational and scientific research, has report a significant breakthrough in the battle against cancer and harmful antibiotic-resistant strains of bacteria including the “superbug” deadliness of MRSA, and Pseudomonas aeruginosa (PS).

Anthony Holland, president of Novobiotronics, reported the findings of recent laboratory research done in collaboration with the State University of New York (Stony Brook, USA) that their new electronic treatment of antibiotic resistant MRSA and PS has both a bacteriostatic effect as well as a bactericidal effect when used in combination with tiny amounts of conventional antibiotics to which the deadly organisms are otherwise normally resistant.

The current standard medical treatment of antibiotic-resistant bacterial infections utilizes combinations of different types of antibiotics, but those combinations can result in very serious and even dangerous side effects. Physicians even induce some patients into a coma to reduce the severity of the drug side effects.

Novobiotronics’ new technology involves the use of a “plasma antenna,” a type of a helium gas filled fluorescent light used to broadcast oscillating pulsed electric fields at cancer cells and bacteria. These OPEFs can kill cancer cells, slow the growth rate of the cancer cells and bacteria greatly, and actually quash the bacteria’s ability to resist antibiotics. When used in combination with very small amounts of a traditional antibiotic, OPEF has demonstrated an ability to destroy MRSA and PS bacteria.

Novobiotronics’ collaborators from the State University of New York presented their joint findings at a September 2013 meeting of the American Society for Microbiology, held in Denver (CO, USA).

Related Links:

Novobiotronics
State University of New York



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: To adhere to catheters and start urinary tract infections, bacteria extend microscopic fibers with sticky proteins at their ends. Researchers have developed a vaccine that blocks the EbpA protein, visible as a white bulge above, and stops infections in mice (Photo courtesy of Dr. John Heuser, Washington University School of Medicine).

Blocking Binding of Bacteria to Fibrinogen Prevents Biofilm Formation and Catheter-Associated Bladder Infection in Mice

A team of molecular microbiologists has identified and targeted a critical step in biofilm formation and developed a vaccine that prevents catheter-associated urinary tract infections in mice.... Read more

Drug Discovery

view channel
Image: S-649266 has more robust antibacterial activity than established antibiotics against multidrug-resistant bacteria (Photo courtesy of Shionogi).

Novel Antibiotic Shows Potential for Broad Range of Infections

The emergence of bacterial resistance to known antibacterial agents is becoming a major challenge in treating the infection caused by multi drug resistant (MDR) bacteria. In order to treat bacterial... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.